InMed Pharmaceuticals Inc. Reports Q3 2025 Financial Results: A Step Forward Amid Challenges
InMed Pharmaceuticals Inc. (NASDAQ: INM), a clinical-stage pharmaceutical company dedicated to developing cannabinoid-based therapies for unmet medical needs, released its financial results for the third quarter of 2025. Despite ongoing challenges, the company continues to advance its product pipeline while navigating the complexities of funding and operational growth.
1. Overview of Financial Performance
InMed’s Q3 2025 report highlights a mixed bag of results as the company strives to establish its position in the pharmaceutical landscape. For the three months ended March 31, 2025, InMed reported a net loss of $2.12 million, widening from a loss of $1.72 million in the same quarter last year. This increase in losses reflects the company's ongoing investment in research and development (R&D) initiatives aimed at advancing its proprietary drug candidates.
| May 2024 | May 2025 | |
|---|---|---|
Net Income | -6.05M | -8.37M |
Profit | -6.08M | -8.31M |
Net Income Continuing | -6.08M | -8.31M |
Income Tax Expense | 13.1K | 7.1K |
Pretax Income | -6.07M | -8.30M |
Non-operating Income | -24.55K | -7.67K |
Operating Income | -6.68M | -8.42M |
Revenue | 5.62M | 4.92M |
Costs and Expenses | 12.30M | 13.34M |
Cost of Revenue | 3.42M | 3.58M |
Operating Expenses | 8.88M | 9.75M |
Depreciation, Depletion & Amortization | 218.2K | 214.8K |
Research & Development | 3.18M | 3.94M |
Selling, General & Administrative | 5.44M | 5.51M |
Other Operating Expenses | 36.71K | 75.81K |
Revenue and Operating Results
InMed's revenue for Q3 2025 reached $1.26 million, marking an increase from $1.17 million in Q3 2024. This growth is attributed to the continued demand for rare cannabinoid products manufactured by the company’s subsidiary, BayMedica. However, the overall financial health is impacted by rising operating expenses, which totaled $3.39 million for the quarter, compared to $3.01 million in the prior year's quarter.
Operating expenses were driven up by a 45% increase in R&D expenses, totaling $909.6K, as the company intensified its efforts in drug development, particularly for INM-901, INM-089, and INM-755. General and administrative expenses decreased slightly by 5% to $1.32 million.
Segment Performance: InMed Pharma vs. BayMedica
- InMed Pharma Segment: The InMed Pharma segment saw significant R&D investments leading to increased costs but has yet to yield commercial products.
- BayMedica Segment: In contrast, the BayMedica commercial segment experienced an 8% increase in sales, attributed to enhanced marketing efforts, although costs of goods sold surged by 23%, reflecting a focus on lower-margin products.
2. Balance Sheet and Cash Position
As of March 31, 2025, InMed's total assets amounted to $9.27 million, a significant decrease from $13.35 million reported in the previous year. This decline is primarily due to reduced cash reserves, which stood at $4.67 million, down from $7.60 million a year earlier. The company’s liabilities remained steady at $2.25 million, maintaining a balance in financial obligations.
| May 2024 | May 2025 | |
|---|---|---|
Total Assets | 13.35M | 9.27M |
Total Current Assets | 10.06M | 6.41M |
Cash and Equivalents | 7.60M | 4.67M |
Short-term Investments | 43.08K | 40.58K |
Net Inventories | 1.19M | 813.9K |
Accounts Receivable | 207.6K | 367.8K |
Prepaid Expenses | 1.01M | 507.8K |
Total Non-current Assets | 3.29M | 2.86M |
Intangible Assets | 1.82M | 1.66M |
Net PP&E | 1.37M | 1.10M |
Other Non-current Assets | 100K | 100K |
Total Liabilities and Equity | 13.35M | 9.27M |
Total Liabilities | 2.25M | 2.25M |
Total Current Liabilities | 1.52M | 1.83M |
Accounts Payable and Accrued Liabilities | 1.18M | 1.40M |
Current Debt | 345.5K | 429.2K |
Total Non-current Liabilities | 725.2K | 419.3K |
Other Non-current Liabilities | 725.2K | 419.3K |
Total Equity and Non-controlling Interests | 11.10M | 7.02M |
Total Equity | 11.10M | 7.02M |
Liquidity Challenges and Funding Requirements
InMed faces pressing liquidity challenges, with substantial operating losses and negative cash flow since its inception. The company has relied heavily on equity financing to sustain its operations. With cash reserves dwindling, InMed has indicated substantial doubt about its ability to continue as a going concern within the next year without raising additional capital.
To address funding needs, InMed has entered into a Standby Equity Purchase Agreement (SEPA) to sell up to $10 million in Common Shares over the next three years. Additionally, the company has amended its At-the-Market (ATM) Offering Agreement to facilitate further equity sales.
3. Recent Developments and Future Outlook
InMed has made significant strides in its drug development pipeline. Notably, promising results from long-term preclinical studies of INM-901 have shown a reduction in neuroinflammation, indicating potential efficacy in treating Alzheimer’s disease. The INM-089 program is also advancing, with a newly selected intravitreal formulation ready for upcoming preclinical studies.
Despite the financial hurdles, InMed's commitment to its innovative product pipeline remains steadfast. The company has scheduled a special meeting of shareholders to approve the issuance of additional shares under the SEPA, signifying its proactive approach to securing necessary capital.
4. Conclusion
InMed Pharmaceuticals Inc. continues to navigate a challenging financial landscape while making critical advancements in its drug development programs. As the company seeks to bolster its financial position through strategic funding initiatives, stakeholders will be closely monitoring its progress and the potential impact on its innovative product offerings in the near future. The next quarter will be pivotal for InMed as it aims to convert its research efforts into commercial success amidst ongoing financial pressures.
